D. Boral Capital Maintains Buy on Immunic, Lowers Price Target to $4
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $8 to $4.
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $8 to $4.